110 related articles for article (PubMed ID: 16051524)
1. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors.
Garanger E; Boturyn D; Jin Z; Dumy P; Favrot MC; Coll JL
Mol Ther; 2005 Dec; 12(6):1168-75. PubMed ID: 16051524
[TBL] [Abstract][Full Text] [Related]
2. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.
Jin ZH; Josserand V; Razkin J; Garanger E; Boturyn D; Favrot MC; Dumy P; Coll JL
Mol Imaging; 2006 Jul; 5(3):188-97. PubMed ID: 16954034
[TBL] [Abstract][Full Text] [Related]
4. "Polymultivalent" Polymer-Peptide Cluster Conjugates for an Enhanced Targeting of Cells Expressing α
Duret D; Grassin A; Henry M; Jacquet T; Thoreau F; Denis-Quanquin S; Coll JL; Boturyn D; Favier A; Charreyre MT
Bioconjug Chem; 2017 Sep; 28(9):2241-2245. PubMed ID: 28767233
[TBL] [Abstract][Full Text] [Related]
5. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4).
Jin ZH; Razkin J; Josserand V; Boturyn D; Grichine A; Texier I; Favrot MC; Dumy P; Coll JL
Mol Imaging; 2007; 6(1):43-55. PubMed ID: 17311764
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Bianchi A; Arosio D; Perego P; De Cesare M; Carenini N; Zaffaroni N; De Matteo M; Manzoni L
Org Biomol Chem; 2015 Jul; 13(27):7530-41. PubMed ID: 26074454
[TBL] [Abstract][Full Text] [Related]
7. High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors.
Shaw SK; Schreiber CL; Roland FM; Battles PM; Brennan SP; Padanilam SJ; Smith BD
Bioorg Med Chem; 2018 May; 26(8):2085-2091. PubMed ID: 29548784
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes.
Garcia Ribeiro RS; Belderbos S; Danhier P; Gallo J; Manshian BB; Gallez B; Bañobre M; de Cuyper M; Soenen SJ; Gsell W; Himmelreich U
Int J Nanomedicine; 2019; 14():5911-5924. PubMed ID: 31534330
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: In vitro and in vivo evaluation.
Choi J; Rustique E; Henry M; Guidetti M; Josserand V; Sancey L; Boutet J; Coll JL
Int J Pharm; 2017 Nov; 532(2):677-685. PubMed ID: 28279737
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
11. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.
Sancey L; Lucie S; Garanger E; Elisabeth G; Foillard S; Stéphanie F; Schoehn G; Guy S; Hurbin A; Amandine H; Albiges-Rizo C; Corinne AR; Boturyn D; Didier B; Souchier C; Catherine S; Grichine A; Alexeï G; Dumy P; Pascal D; Coll JL; Jean-Luc C
Mol Ther; 2009 May; 17(5):837-43. PubMed ID: 19259068
[TBL] [Abstract][Full Text] [Related]
12. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif.
Aoki Y; Hosaka S; Kawa S; Kiyosawa K
Cancer Gene Ther; 2001 Oct; 8(10):783-7. PubMed ID: 11687901
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging.
Goutayer M; Dufort S; Josserand V; Royère A; Heinrich E; Vinet F; Bibette J; Coll JL; Texier I
Eur J Pharm Biopharm; 2010 Jun; 75(2):137-47. PubMed ID: 20149869
[TBL] [Abstract][Full Text] [Related]
14. Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.
Garanger E; Boturyn D; Coll JL; Favrot MC; Dumy P
Org Biomol Chem; 2006 May; 4(10):1958-65. PubMed ID: 16688341
[TBL] [Abstract][Full Text] [Related]
15. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
[TBL] [Abstract][Full Text] [Related]
16. Cyclic RGD functionalized gold nanoparticles for tumor targeting.
Arosio D; Manzoni L; Araldi EM; Scolastico C
Bioconjug Chem; 2011 Apr; 22(4):664-72. PubMed ID: 21434651
[TBL] [Abstract][Full Text] [Related]
17. Integrin specificity of the cyclic Arg-Gly-Asp motif and its role in integrin-targeted gene transfer.
Wittekindt C; Böttger M; Höltje HD; Schäfer-Korting M; Cartier R; Haberland A
Biotechnol Appl Biochem; 2004 Dec; 40(Pt 3):281-90. PubMed ID: 14992694
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Pilkington-Miksa M; Arosio D; Battistini L; Belvisi L; De Matteo M; Vasile F; Burreddu P; Carta P; Rassu G; Perego P; Carenini N; Zunino F; De Cesare M; Castiglioni V; Scanziani E; Scolastico C; Casiraghi G; Zanardi F; Manzoni L
Bioconjug Chem; 2012 Aug; 23(8):1610-22. PubMed ID: 22770429
[TBL] [Abstract][Full Text] [Related]
19. Functionalization of small rigid platforms with cyclic RGD peptides for targeting tumors overexpressing αvβ3-integrins.
Morlieras J; Dufort S; Sancey L; Truillet C; Mignot A; Rossetti F; Dentamaro M; Laurent S; Vander Elst L; Muller RN; Antoine R; Dugourd P; Roux S; Perriat P; Lux F; Coll JL; Tillement O
Bioconjug Chem; 2013 Sep; 24(9):1584-97. PubMed ID: 23978076
[TBL] [Abstract][Full Text] [Related]
20. Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.
Handgraaf HJM; Boonstra MC; Prevoo HAJM; Kuil J; Bordo MW; Boogerd LSF; Sibinga Mulder BG; Sier CFM; Vinkenburg-van Slooten ML; Valentijn ARPM; Burggraaf J; van de Velde CJH; Frangioni JV; Vahrmeijer AL
Oncotarget; 2017 Mar; 8(13):21054-21066. PubMed ID: 28416744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
